BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC

Reuters

2025/12/31

BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC

BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin (Oz-V) into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma (OPSCC). Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618495) on December 31, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2595019776"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2595019776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2595019776?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595019776","market":"us","top_or_hot":-1,"title":"BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin (Oz-V) into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma (OPSCC). Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618495) on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-31 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin (Oz-V) into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma (OPSCC). Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618495) on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL3Mn76f:1","article_id":"2595019776","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595019776","pubTimestamp":1767182417,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin  into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma . Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BCAB":"BioAtla, Inc.","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股"},"translate_title":"BioAtla与Inversagen AI合作推进Oz-V Senolytic疗法治疗OPSCC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAB":0.9,"NDAQ":0.9},"content_text":"BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC\n    \n\n        BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin (Oz-V) into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma (OPSCC). Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618495) on December 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}